Canada Diabetes Care Devices Market - Growth, Trends, and Forecasts (2019 - 2024)

The Market is segmented by Management Devices (Insulin Pumps, Insulin Pens, Syringes, Cartridges, and Jet Injectors) and Monitoring Devices (Self-monitoring Blood Glucose (Hospital and Personal use) and Continuous Glucose Monitoring), and Geography.

Market Snapshot

Canada Diabetes Devices Summary
Study Period:

2012-2024

Base Year:

2018

Key Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

  • The Canada diabetes care devices market is expected to register a CAGR of about 10.02% during the forecast period (2019-2024).
  • Monitoring devices are anticipated to dominate the market during the forecast period, owing to the rising prevalence of diabetes and an increase in the number of device users in the country.
  • There has been a significant rise in insulin delivery systems technology, from insulin injections to insulin pumps.
  • Technological innovations and advances give many conveniences in measuring the blood glucose levels. One such advancement in monitoring the blood glucose levels has established with continuous glucose monitoring devices. 

Scope of the Report

The Market is segmented by Management Devices (Insulin Pumps, Insulin Pens, Syringes, Cartridges, and Jet Injectors) and Monitoring Devices (Self-monitoring Blood Glucose (Hospital and Personal use) and Continuous Glucose Monitoring), and Geography.

By Monitoring Devices Self-monitoring Blood Glucose Devices Glucometer Devices
Blood Glucose Test Strips
Lancets
Hospital
Personal
Continuous Glucose Monitoring Devices Sensors
Receivers
 
By Management Devices Insulin Pump Insulin Pump Device
Insulin Pump Reservoir
Infusion Set
Insulin Syringes  
Cartridges in Reusable pens
Disposable Insulin Pens
Jet Injectors

Key Market Trends

Test strips occupy the highest market share among the Monitoring devices for the year 2018

  • Monitoring devices include self-monitoring blood glucose devices (SMBG) and continuous glucose monitoring devices (CGM), where SMBG devices had the highest share in 2018, with a revenue of USD 0.2 billion and test strips occupy 0.1 billion.
  • The frequency of monitoring glucose levels depends on the type of diabetes, which varies from patient to patient.
  • Type-1 diabetic patients need to check their blood glucose levels at regular intervals, to monitor their blood glucose levels and adjust the insulin dosing accordingly.
  • Therefore, if a patient performs 5-6 tests in a day, the average expenditure on test strips would be more than USD 100/month. These expenses add to the already high diabetes management costs and are impeding market growth.
Canada Diabetes Devices Key Trend 1

To understand key trends, Download Sample Report

Insulin Pumps Occupy the Highest Share in the Management Devices Segment

  • The use of Insulin pumps is rising among developed countries. These are the devices which mimic the human pancreas, i.e., there would be continuous subcutaneous insulin administration in small amounts.
  • Insulin pumps deliver rapid- or short-acting insulin 24 hours a day through a catheter placed under the skin.
  • The insulin pumps usage among Canadian patients increased due to the accurate dosage of administration and patients who are not able to meet the insulin requirements accurately.
  • Thus, the CAGR growth is expected to be 4.83% during the forecast period.
Canada Diabetes Devices Key Trend 2

Competitive Landscape

  • There have been constant innovations driven by manufacturers to compete in the market. The major players, such as Abbott and Medtronic, have undergone many mergers, acquisitions, and partnerships, to establish market dominance, while also adhering to organic growth strategies, which is evident from the R&D spending of these companies.
  • The manufacturers of insulin delivery devices are spending a massive amount on the R&D of the devices. For example, Novo Nordisk partnered with Abbott Diabetes Care, which may help to enable insulin data to be shared between Novo Nordisk connected insulin pens and digital health tools compatible with FreeStyle Libre portfolio of products.

Major Players

  1. Abbott
  2. Dexcom
  3. Roche
  4. Medtronic
  5. Johnson and Johnson

* Complete list of players covered available in the table of contents below

Canada Diabetes Device By company

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. Market Segmentation

    1. 5.1 By Product

      1. 5.1.1 By Monitoring Devices, Value and Volume (2012-2024)

        1. 5.1.1.1 Self-monitoring Blood Glucose Devices

          1. 5.1.1.1.1 Glucometer Devices

            1. 5.1.1.1.1.1 Hospital

            2. 5.1.1.1.1.2 Personal

          2. 5.1.1.1.2 Blood Glucose Test Strips

            1. 5.1.1.1.2.1 Hospital

            2. 5.1.1.1.2.2 Personal

          3. 5.1.1.1.3 Lancets

            1. 5.1.1.1.3.1 Hospital

            2. 5.1.1.1.3.2 Personal

        2. 5.1.1.2 Continuous Glucose Monitoring

          1. 5.1.1.2.1 Sensors

          2. 5.1.1.2.2 Receivers

      2. 5.1.2 By Management Devices, Value and Volume (2012-2024)

        1. 5.1.2.1 Insulin Pump

          1. 5.1.2.1.1 Insulin Pump Device

          2. 5.1.2.1.2 Insulin Pump Reservoir

          3. 5.1.2.1.3 Infusion Set

        2. 5.1.2.2 Insulin Syringes

        3. 5.1.2.3 Cartridges in Reusable pens

        4. 5.1.2.4 Insulin Disposable Pens

        5. 5.1.2.5 Jet Injectors

    2. 5.2 Geography

      1. 5.2.1 Canada (Value and Volume, 2012 - 2024)

        1. 5.2.1.1 By Monitoring Device (Self-monitoring Blood Glucose Devices, Continuous Glucose Monitoring)

        2. 5.2.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)

        3. 5.2.1.3 By Company (Roche, Dexcom, Abbott, Johnson and Johnson, Medtronics, Novo Nordisk, and Others)

  6. 6. MARKET INDICATORS

    1. 6.1 Type 1 Diabetes Population (2012-2024)

    2. 6.2 Type 2 Diabetes Population (2012-2024)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 COMPANY PROFILES

      1. 7.1.1 Abbott Diabetes Care

      2. 7.1.2 Roche

      3. 7.1.3 Johnson & Johnson

      4. 7.1.4 Dexcom

      5. 7.1.5 Medtronic

      6. 7.1.6 Arkray

      7. 7.1.7 Ascensia Diabetes Care

      8. 7.1.8 Agamatrix Inc.

      9. 7.1.9 Novo Nordisk

      10. 7.1.10 Eli Lilly

    2. 7.2 COMPANY SHARE ANALYSIS

      1. 7.2.1 Roche

      2. 7.2.2 Johnson & Johnson

      3. 7.2.3 Abbott Diabetes Care

      4. 7.2.4 Dexcom

      5. 7.2.5 Medtronics

      6. 7.2.6 Novo Nordisk

      7. 7.2.7 Others

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please Enter a Valid Message!


Complete your payment details below

Shipping & Billing Information

Payment Information